Plasma neurofilament light in Huntington’s disease: A marker for disease onset, but not symptom progression

OBJECTIVE: To investigate whether plasma NfL levels correlate with clinical symptom severity in premanifest (PM) and manifest HD (HD) individuals, and whether a NfL cut-point could distinguish PM from HD patients with reasonable accuracy. METHOD: 98 participants (33 control, 26 PM, 39 HD), underwent...

Descripción completa

Detalles Bibliográficos
Autores principales: Parkin, Georgia M., Corey-Bloom, Jody, Snell, Chase, Castleton, Jordan, Thomas, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083556/
https://www.ncbi.nlm.nih.gov/pubmed/33940564
http://dx.doi.org/10.1016/j.parkreldis.2021.04.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083556/
https://www.ncbi.nlm.nih.gov/pubmed/33940564
http://dx.doi.org/10.1016/j.parkreldis.2021.04.017

Ejemplares similares